研究疾病:
|
慢性乙型病毒性肝炎肝纤维化
|
研究疾病代码:
|
|
Target disease:
|
Liver Fibrosis due to Chronic Hepatitis B Virus Infection
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
评价克癀胶囊治疗慢性乙型病毒性肝炎肝纤维化的有效性和安全性。
|
Objectives of Study:
|
Evaluate the efficacy and safety of Kehuang capsule in the treatment of liver fibrosis due to chronic hepatitis B virus infection.
|
药物成份或治疗方案详述:
|
本试验是一项随机、双盲、安慰剂对照、多中心临床试验,分为试验组(抗病毒治疗+克癀胶囊组)和对照组(抗病毒治疗+克癀胶囊模拟剂组),共计随机入选144 例受试者,多中心同时进行,其中20%受试者(试验组14 例,对照组14 例)须接受肝穿刺活检组织病理学检查。随机入组后受试者接受试验药物和抗病毒治疗,并按规定进行5次访视观察。
|
Description for medicine or protocol of treatment in detail:
|
This trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial, divided into an experimental group (antiviral treatment + Kehuang capsule) and a control group (antiviral treatment + Kehuang capsule placebo). 144 participants will be randomly recruited in multiple centers at the same time, among which 20% of participants (14 in the experimental group and 14 in the control group) will receive liver biopsy assessment. After the randomized recruitment, the participants will receive the experimental drug and antiviral treatment and will be observed for 5 visits as required.
|
纳入标准:
|
1) 18-65 周岁成年患者,性别不限。
2) 符合肝纤维化诊断标准:符合下列情况之一:①肝组织穿刺活检病理结果符合肝纤维化Ishak 诊断标准,且分期为2-5 期;②FibroScan 检测值(LSM)≥9.0kPa。
3) 临床诊断证实HBsAg 阳性的慢性乙型肝炎患者。
4) 符合中医湿热瘀阻的患者。症见:右上腹胀或痛、饮食减少、脘腹胀闷、恶心欲呕、口干苦或口臭、倦怠乏力、小便黄、大便粘滞秽臭或干结、舌质红或有瘀点、苔黄腻、脉弦数或弦滑数。
5) 患者表示知情同意、自愿受试并签署知情同意书。
|
Inclusion criteria
|
1) Adult patients aged 18-65 years old with no restriction on gender.
2) Meet the diagnostic criteria for liver fibrosis: one of the followings: ①the pathological results of liver biopsy assessment meet the Ishak diagnostic criteria for liver fibrosis and at stages 2-5; ②the FibroScan test value (LSM)≥9.0 kPa.
3) Chronic hepatitis B patients with clinically confirmed HBsAg positivity.
4) Patients with damp-heat stasis in traditional Chinese medicine. Symptoms: distension or pain in the right upper abdomen, reduced diet, distention and stuffiness in the abdomen, nausea and vomiting, dry and bitter mouth or bad breath, tiredness and weakness, yellow urine, sticky and foul-smelling stools or dry stools, red tongue or petechiae, yellow and greasy coating, and string or smooth pulse.
5) Patients gave informed consent, volunteered to be tested, and signed the informed consent form.
|
排除标准:
|
1) 接受慢性乙型肝炎(CHB)抗病毒治疗不足一年的患者。
2) 合并肝脏肿瘤、肝胆寄生虫病、肝硬化失代偿期的患者。
3) 合并心血管、肺、肾、内分泌、神经及血液系统严重疾病者(如室性快速性心率失常、心肌梗塞、活动性肺结核、严重肺部感染、慢性肾病、肾功能不全、各种严重贫血、血友病以及恶性肿瘤、精神病患者。
4) PLT≤60×109/L,TBIL>2×ULN,ALT≥8×ULN 和/或AST≥8×ULN 者,血肌酐(Scr)>正常参考值上限者。
5) 妊娠期妇女或哺乳期妇女,生育年龄的受试者(包括有异性性行为的男性受试者及其有生育潜能的女性伴侣)从筛选期到停药后6个月内有妊娠计划或不愿采取有效避孕措施者。
6) 基线前6个月内吸毒或滥用药物史以致可能影响试验结果评价的患者。
7) 酒精性肝病、自身免疫性肝炎(ANA阳性)、药物成瘾或酒精依赖者。
8) 入选前3个月内接受可能有抗纤维化作用的中成药治疗者。
9) 入选前3个月内参加其它临床试验者。
10) 过敏体质或有严重过敏史者,尤其是试验药物及成分过敏者。
11) 丙型肝炎病毒抗体、梅毒血清特异性抗体或艾滋病毒抗原/抗体检查异常者。
12) 研究者认为不宜参加本临床试验患者及其他原因不配合、依从性差等患者。
|
Exclusion criteria:
|
1) Patients receiving antiviral therapy for chronic hepatitis B (CHB) for less than one year.
2) Patients with liver tumors, hepatobiliary parasitic disease, or cirrhosis in the decompensated stage
3) Patients with combined serious cardiovascular, pulmonary, renal, endocrine, neurological, and hematologic diseases (e.g. ventricular tachyarrhythmia, myocardial infarction, active tuberculosis, severe pulmonary infection, chronic kidney disease, renal insufficiency, various types of severe anemia, hemophilia, malignant tumor, and psychiatric disease).
4) Patients with PLT≤60×10^9/L, TBIL>2×ULN, ALT≥8×ULN and/or AST≥8×ULN, and serum creatinine (Scr)>upper limit of normal reference value.
5) Pregnant or lactating women, participants of childbearing age (including male participants who have heterosexual sex and their female partners of childbearing potential) who have a pregnancy plan or are unwilling to use effective contraception from the screening period to 6 months after discontinuation of the drug.
6) Patients with a history of drug or substance abuse within 6 months prior to the baseline that may affect the evaluation of the test results.
7) Patients with alcoholic liver disease, autoimmune hepatitis (ANA positive), drug addiction, or alcohol dependence.
8) Patients treated with proprietary Chinese medicines that may have antifibrotic effects within 3 months prior to enrollment.
9) Persons who participated in other clinical trials within 3 months before recruitment.
10) Persons with allergies or a history of severe allergies, especially to test drugs and components.
11) Persons with abnormal results in hepatitis C virus antibody, syphilis serum-specific antibody, or HIV antigen/antibodies.
12) Patients who are considered by the investigator to be ineligible to participate in this clinical trial and patients who are uncooperative or poorly compliant for other reasons.
|
研究实施时间:
Study execute time:
|
从From
2022-05-30
至To
2024-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2022-09-15
至To
2023-09-15
|